Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial (Q35071954)

6 August 2017

title

Cystatin C-based renal function changes after antiretroviral initiation: a substudy of a randomized trial (English)

1 reference

6 August 2017

main subject

anti-retroviral agent

0 references

5

Paul E Sax

1 reference

6 August 2017

8

Grace A McComsey

1 reference

6 August 2017

4

Eric S Daar

1 reference

6 August 2017

Samir K Gupta

1

1 reference

6 August 2017

Douglas Kitch

2

1 reference

6 August 2017

Camlin Tierney

3

1 reference

6 August 2017

Kathleen Melbourne

6

1 reference

6 August 2017

Belinda Ha

7

1 reference

6 August 2017

AIDS Clinical Trials Group Study A5224s Team

9

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 March 2014

1 reference

Open Forum Infectious Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

1

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

ofu003

1 reference

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported

6 August 2017

copyright license

start time

28 October 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Cystatin C versus creatinine in determining risk based on kidney function

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Estimating glomerular filtration rate from serum creatinine and cystatin C.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Expressing the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) cystatin C equations for estimating GFR with standardized serum cystatin C values

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Cystatin C identifies chronic kidney disease patients at higher risk for complications

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Mechanism of active renal tubular efflux of tenofovir

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Cystatin C and the risk of death and cardiovascular events among elderly persons

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Prediction of creatinine clearance from serum creatinine

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy

8 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Cystatin C in HIV-infected patients: promising but not yet ready for prime time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FOFID%2FOFU003

Acute interstitial nephritis associated with atazanavir, a new protease inhibitor

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4324191

Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection

27 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25734077

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25734077

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/OFID/OFU003

1 reference

release_uitwznoiorhzrlqygusyirc6pq

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/uitwznoiorhzrlqygusyirc6pq

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

4324191

1 reference

6 August 2017

1 reference